RecruitingNCT07623148

GLP-1 RA Cessation and Gastric Ultrasound Findings

Time-dependent Association Between Cessation of Glucagon-like Peptide-1 Receptor Agonists and Residual Gastric Contents Assessed by Point-of-care Gastric Ultrasound: a Prospective Observational Study


Sponsor

Wonkwang University Hospital

Enrollment

186 participants

Start Date

Jul 1, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective observational study will evaluate the association between the time interval since the last dose of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and residual gastric contents before elective surgery. Adult patients receiving GLP-1 RAs and scheduled for elective non-cardiac surgery under general anesthesia will undergo preoperative point-of-care gastric ultrasound. The study will assess whether longer GLP-1 RA cessation intervals are associated with lower ultrasound-estimated gastric volume and a lower frequency of high-risk gastric contents. Body mass index will also be evaluated as a potential modifier of this association.


Eligibility

Min Age: 19 YearsMax Age: 65 Years

Inclusion Criteria4

  • Adults aged 18 years or older.
  • Patients receiving a glucagon-like peptide-1 receptor agonist.
  • Patients scheduled for elective non-cardiac surgery requiring general anesthesia.
  • Patients able to provide written informed consent.

Exclusion Criteria4

  • Emergency surgery.
  • History of prior gastric surgery.
  • Known gastroparesis or severe gastroesophageal reflux disease.
  • Declined or unable to provide written informed consent.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERGLP-1 RA Cessation Interval

Observed exposure defined as the number of days between the participant's last glucagon-like peptide-1 receptor agonist dose and elective surgery. Participants were categorized according to time since last dose: 3 days or less, 4 to 7 days, and 8 days or more. No GLP-1 receptor agonist was assigned, administered, continued, or discontinued by the study protocol; medication management followed usual clinical care.


Locations(1)

Wonkwang University School of Medicine Hospital

Iksan, Jeonbuk-do, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07623148


Related Trials